These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153 [TBL] [Abstract][Full Text] [Related]
3. Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma. Gallou C; Longuemaux S; Deloménie C; Méjean A; Martin N; Martinet S; Palais G; Bouvier R; Droz D; Krishnamoorthy R; Junien C; Béroud C; Dupret JM Pharmacogenetics; 2001 Aug; 11(6):521-35. PubMed ID: 11505222 [TBL] [Abstract][Full Text] [Related]
4. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Gallou C; Joly D; Méjean A; Staroz F; Martin N; Tarlet G; Orfanelli MT; Bouvier R; Droz D; Chrétien Y; Maréchal JM; Richard S; Junien C; Béroud C Hum Mutat; 1999; 13(6):464-75. PubMed ID: 10408776 [TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Gallou C; Chauveau D; Richard S; Joly D; Giraud S; Olschwang S; Martin N; Saquet C; Chrétien Y; Méjean A; Correas JM; Benoît G; Colombeau P; Grünfeld JP; Junien C; Béroud C Hum Mutat; 2004 Sep; 24(3):215-24. PubMed ID: 15300849 [TBL] [Abstract][Full Text] [Related]
6. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521 [TBL] [Abstract][Full Text] [Related]
7. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493 [TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors. Hemminki K; Jiang Y; Ma X; Yang K; Egevad L; Lindblad P Carcinogenesis; 2002 May; 23(5):809-15. PubMed ID: 12016154 [TBL] [Abstract][Full Text] [Related]
9. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750 [TBL] [Abstract][Full Text] [Related]
10. Von Hippel-Lindau syndrome. A pleomorphic condition. Friedrich CA Cancer; 1999 Dec; 86(11 Suppl):2478-82. PubMed ID: 10630173 [TBL] [Abstract][Full Text] [Related]
11. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541 [TBL] [Abstract][Full Text] [Related]
12. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Prowse AH; Webster AR; Richards FM; Richard S; Olschwang S; Resche F; Affara NA; Maher ER Am J Hum Genet; 1997 Apr; 60(4):765-71. PubMed ID: 9106522 [TBL] [Abstract][Full Text] [Related]
13. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. Brauch H; Weirich G; Hornauer MA; Störkel S; Wöhl T; Brüning T J Natl Cancer Inst; 1999 May; 91(10):854-61. PubMed ID: 10340905 [TBL] [Abstract][Full Text] [Related]
14. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. Maher ER; Webster AR; Richards FM; Green JS; Crossey PA; Payne SJ; Moore AT J Med Genet; 1996 Apr; 33(4):328-32. PubMed ID: 8730290 [TBL] [Abstract][Full Text] [Related]
15. Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. Vortmeyer AO; Huang SC; Koch CA; Governale L; Dickerman RD; McKeever PE; Oldfield EH; Zhuang Z Cancer Res; 2000 Nov; 60(21):5963-5. PubMed ID: 11085513 [TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation. Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917 [TBL] [Abstract][Full Text] [Related]
17. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918 [TBL] [Abstract][Full Text] [Related]
19. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Webster AR; Richards FM; MacRonald FE; Moore AT; Maher ER Am J Hum Genet; 1998 Oct; 63(4):1025-35. PubMed ID: 9758595 [TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus. Walker C; Ahn YT; Everitt J; Yuan X Mol Carcinog; 1996 Feb; 15(2):154-61. PubMed ID: 8599582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]